The FDA approved several new therapies for cancers, including the combination of Imfinzi and Imjudo to treat lung cancer, Libtayo for second indication in lung cancer, and Adcetris for younger patients with Hodgkin lymphoma. In COVID-19 news, the agency issued an EUA for Kineret for hospitalized, but indicated bebtelovimab does not neutralize new omicron subvariants. The regulatory agency also accepted NDAs for a Parkinson’s disease therapy and for a therapy used for stem cell mobilization.
Teladoc Health’s CEO weighs in on what a look at the past can tell us about the future.
More practices are directly dispensing oral cancer drugs, bypassing specialty pharmacies. What does this trend mean for patients and healthcare?
Adherence to follow-up examinations is crucial for early identification of recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP).
The tool successfully identified children with high asthma risk as young as 3 years of age. The screening tool was found to be more accurate at predicting asthma, persistent wheezing, and related emergency room visits and hospitalizations than standard screening and diagnostic tools.
Despite differing characteristics, patients have similar responses to treatment regardless of when they were diagnosed with eosinophilic esophagitis (EoE).
Abortion access was a key issue in Pennsylvania and other battleground states. The Affordable Care Act receded into the political background, although voters in South Dakota approved a ballot measure that expanded Medicaid, leaving just 11 states that haven't done so.
The company has made digital health a major focus of its research pipeline in multiple sclerosis.
Symptoms of chronic rhinosinusitis with nasal polyps can be a burden for patients, but Dupixent was able to successfully reduce the number of days with severe symptoms.
Members who receive healthcare through Point32Health Inc.’s programs will now be able to access a device called Nerivio.
The FDA has approved a hepatitis B therapy for adolescents and an oral MEK inhibitor to treat blood cancers. The regulatory agency has granted priority review for an adult RSV vaccine but extended the review for a Pompe disease therapy. Additionally, CytoDyn has withdrawn its BLA for an HIV therapy.
Gilead Sciences reported results from several studies of its antiretroviral.
In a conversation with Managed Healthcare Executive®, Genoa Healthcare Sales Director Jennifer Finocchiaro discusses social determinants of health, the LGBTQ+ community and the demographic contours of the HIV/AIDS epidemic.
Overall survival is considered a more definitive end point. But according to Vinay Prasad, M.D., M.P.H., and colleagues , drugs approved based on progression-free survival and overall response rate were priced higher than those approved based on overall survival.
Thirty-seven percent of insured Americans whose annual income is $80,000 or more even said they avoided care because of cost concerns.
If South Dakota voters approve a ballot initiative on Nov. 8, that will leave 11 states that have not expanded their Medicaid programs under the ACA.
The FDA approved two new novel cancer treatments: a bispecific antibody for multiple myeloma and a regimen of two drugs for liver cancer. The agency also granted priority review to two therapies. One is a novel therapy for C. difficile and the other is for a acute myeloid leukemia drug. The FDA has postponed an advisory committee meeting for an OTC birth control pill and accepted an NDA for new dry eye therapy. Additionally, Genmab submitted applications for a bispecific therapy for large B-cell lymphoma.
This year, funding fell from $10.5 billion in the first quarter down to the lowest funding has been at $4.6 billion today, according to a report from HealthcareDive.
These areas in the new MA territory and existing ones can enjoy some of Cigna's new benefits this year.
The state's child uninsured rate dropped to 6.6% in 2021, its lowest level in recent history. This drop represents a 19% decline from a peak of 8.1% in 2018.
Cigna’s Express Scripts will now manage Centene’s pharmacy benefit services to make prescription medications more accessible and affordable for customers. The multi-year partnership is slated to officially begin Jan. 1, 2024.
Three more cities join the 100-plus others that have endorsed the Medicare for All legislation. City Councils in Denver, Colorado, Gainesville, Florida, and Kent, Ohio passed the resolution in support of the universal program that ends for-profit healthcare.
Many prior authorizations requests still come in by fax. Natural language processing and artificial intelligence can extract and use information from faxes.
In COVID-19 news, the FDA issued an EUA for Novavax booster. The agency has extended review time for new ALS therapy and accepted a supplemental NDA for Camzyos. Additionlly, the FDA granted six months pediatric exclusivity for Eylea.
Patients and providers are having to pay more toward their health plans due to these common radiology services charging more than needed.
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends.
Chester "Bernie" Good, senior medical director for the Center for Value Based Pharmacy Initiatives at UPMC Health Plan, gets in depth on value-based contracts and shares the results of the 2019 contract between UPMC and AstraZeneca for Brilinta. Good addressed value-based contracts last week at AMCP Nexus 2022 conference in National Harbor, Maryland.
In COVID-19 news, the FDA has authorized updated boosters for younger children. The FDA also approved an at-home heart failure therapy, but issued a CRL for a Parkinson’s therapy. The agency has assigned PDUFDA dates for several BLA, including a hemophilia A gene therapy and Eylea for retinopathy in premature infants. Regulators have also announced an Adderall shortage. Additionally, a nonprofit company has begun the application process for OTC version of naloxone.
EQRx has said it will price its PD-1/PDL-1 inhibitor 40% below the price of the entrenched PD-1/PDL-1 inhibitors, says Bhavesh Shah of Boston Medical Center Health System. But there are obstacles looming, including the development of combination therapies.
